Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 11, 2023--

Related Keywords

Massachusetts ,United States ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Israel ,Switzerland ,Canada ,Spain ,American ,Hemophagocytic Lymphohistiocytosis ,Elizabeth Pingpank ,Bristol Myers Squibb ,Sergio Giralt ,Paula Rodriguez Otero ,Steve Bernstein ,Anne Kerber ,Drug Administration ,Nasdaq ,Youtube ,Instagram ,European Medicines Agency ,Division Of Hematologic Malignancies ,Oncologic Drugs Advisory Committee ,Linkedin ,European Union ,Department Of Hematology ,Head Of Late Clinical Development ,American Society Of Hematology ,Memorial Sloan Kettering Cancer Center ,Twitter ,Facebook ,Exchange Commission ,Myers Squibb ,American Society ,Annual Meeting ,Oral Presentation ,Clinica Universidad De Navarra ,Late Clinical Development ,Cell Therapy ,Bristol Myers ,Hematologic Malignancies ,Memorial Sloan Kettering Cancer ,Biologics License Application ,Extended Follow Up ,Poster Presentation ,Important Safety Information ,Macrophage Activation Syndrome ,Sloan Kettering Cancer Center ,Profit Share Agreement ,Release Syndrome ,Risk Evaluation ,Mitigation Strategy ,Igg Secondary Malignancies ,Operate Machinery ,Prescribing Information ,Better Future ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Cautionary Note Regarding Forward Looking ,Bristol Myers Squibb Media Inquiries ,Business Wire ,Region ,